Michael P. Dillon - 07 Sep 2021 Form 4 Insider Report for IDEAYA Biosciences, Inc. (IDYA)

Role: SVP, Chief Scientific Officer
Signature: /s/ Jason Throne, as Attorney-in-Fact for Michael P. Dillon
Issuer symbol: IDYA
Transactions as of: 07 Sep 2021
Net transactions value: -$236,514
Form type: 4
Filing time: 09 Sep 2021, 19:24:12 UTC
Previous filing: 07 Sep 2021
Next filing: 07 Oct 2021
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	IDYA	Common Stock	Options Exercise	$500	+116	+0.15%	$4.31^*	78,905	07 Sep 2021	Direct
transaction	IDYA	Common Stock	Sale	$3,185	-116	-0.15%	$27.46	78,789	07 Sep 2021	Direct	F1, F2
transaction	IDYA	Common Stock	Options Exercise	$30,476	+7,071	+9%	$4.31^*	85,860	08 Sep 2021	Direct
transaction	IDYA	Common Stock	Options Exercise	$47,788	+4,313	+5%	$11.08	90,173	08 Sep 2021	Direct
transaction	IDYA	Common Stock	Sale	$306,559	-11,184	-12%	$27.41	78,989	08 Sep 2021	Direct	F1, F3
transaction	IDYA	Common Stock	Sale	$5,534	-200	-0.25%	$27.67	78,789	08 Sep 2021	Direct	F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	IDYA	Stock Option (Right to Buy)	Options Exercise	$0	-116	-0.18%	$0.000000	66,119	07 Sep 2021	Common Stock	116	$4.31	Direct	F4
transaction	IDYA	Stock Option (Right to Buy)	Options Exercise	$0	-7,071	-11%	$0.000000	59,048	08 Sep 2021	Common Stock	7,071	$4.31	Direct	F4
transaction	IDYA	Stock Option (Right to Buy)	Options Exercise	$0	-4,313	-15%	$0.000000	24,937	08 Sep 2021	Common Stock	4,313	$11.08	Direct	F5

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The transactions reported herein were effected pursuant to the Reporting Person's Rule 10b5-1 trading plan.
F2	This transaction was executed in multiple trades in prices ranging from $27.45 to $27.50, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
F3	This transaction was executed in multiple trades in prices ranging from $26.56 to $27.52, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
F4	25% of the shares subject to the option vest on the first anniversary measured from February 27, 2018 (the "Vesting Commencement Date"), and 1/48th of the total number of shares vest monthly thereafter, such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date.
F5	25% of the shares subject to the option vest on the first anniversary measured from February 19, 2019 (the "Vesting Commencement Date"), and 1/48th of the total number of shares vest monthly thereafter, such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date.